Literature DB >> 700907

Pharmacological reevaluation of gitoxin in man.

M Lesne.   

Abstract

The aim of the present investigation was to reevaluate the pharmacokinetic and pharmacodynamic parameters of gitoxin in man. Gitoxin given as a solution is quasi-completely absorbed after oral administration in a fasting man. A dose of 1.5 mg modifies the left ventricular ejection time index (LVETI) as digoxin or digitoxin does. The biological half-life of gitoxin calculated on the basis of plasma concentrations or urinary data is about one day. The urinary elimination of gitoxin is smaller than 21% of the dose. Therefore the two main advantages of gitoxin versus digoxin or digitoxin are: 1) its short biological half-life and 2) its elimination being less dependent on the renal function of the patient.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 700907

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  3 in total

1.  The binding of gitoxin to human plasma proteins.

Authors:  N Verbeke; P Pellegrin; A Vienne; M Lesne
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

2.  Hepatic clearance of gitoxin: pharmacokinetic study on rabbit isolated liver. Influence of protein binding and comparison with digoxin.

Authors:  P Pellegrin; M Lesne
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983       Impact factor: 2.441

3.  Isolation and mass spectrometric identification of gitoxin metabolites excreted in bile.

Authors:  L N Kadima; G Lhoest; M Lesne
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.